AUB ScholarWorks

Patients with osteoporosis prefer once weekly to once daily dosing with alendronate

Show simple item record

dc.contributor.author Kendler D.
dc.contributor.author Kung A.W.C.
dc.contributor.author Fuleihan G.E.-H.
dc.contributor.author Gonzalez Gonzalez J.G.
dc.contributor.author Gaines K.A.
dc.contributor.author Verbruggen N.
dc.contributor.author Melton M.E.
dc.contributor.editor
dc.date Jul-2004
dc.date.accessioned 2017-10-05T15:37:38Z
dc.date.available 2017-10-05T15:37:38Z
dc.date.issued 2004
dc.identifier 10.1016/j.maturitas.2003.12.012
dc.identifier.isbn
dc.identifier.issn 03785122
dc.identifier.uri http://hdl.handle.net/10938/15850
dc.description.abstract Objectives: Once weekly dosing of alendronate has been shown to provide equivalent efficacy to once daily dosing for treatment of osteoporosis in postmenopausal women. Whether patients will prefer weekly dosing to daily dosing for a chronic condition such as osteoporosis has not been studied. The aim of this international study was to assess preference for the weekly or daily dosing regimen of alendronate among postmenopausal women with osteoporosis. Methods: This randomised open-label crossover study was conducted at 45 study sites in 19 countries. Four hundred and six postmenopausal women with osteoporosis were assigned randomly to treatment with either alendronate 70 mg once weekly for 4 weeks followed by alendronate 10 mg once daily for 4 weeks or vice versa. The main outcome was the responses of the participants to the Dosing Regimen Questionnaire administered at the end of the study. Results: Of the participants expressing a preference, 84percent preferred the once weekly dosing regimen with alendronate to the once daily dosing regimen. In addition, the once weekly regimen was considered by 87percent of the participants to be more convenient and was the regimen most of the participants (84percent) would be more willing to take for a long period of time (P0.001 for each parameter). Conclusions: The majority of postmenopausal women with osteoporosis preferred the once weekly to the once daily dosing regimen of alendronate. Physicians should consider patient preference for dosing regimen when selecting the appropriate treatment for osteoporosis. © 2004 Elsevier Ireland Ltd. All rights reserved.
dc.format.extent
dc.format.extent Pages: (243-251)
dc.language English
dc.publisher CLARE
dc.relation.ispartof Publication Name: Maturitas; Publication Year: 2004; Volume: 48; no. 3; Pages: (243-251);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Patients with osteoporosis prefer once weekly to once daily dosing with alendronate
dc.type Conference Paper
dc.contributor.affiliation Kendler, D., St. Vincent's Hospital, 120-809 W 41 Avenue, Vancouver, BC V5Z 2N6, Canada
dc.contributor.affiliation Kung, A.W.C., Queen Mary Hospital, Hong Kong, Hong Kong
dc.contributor.affiliation Fuleihan, G.E.-H., American University, Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation González González, J.G., Univ. Auton. de Nuevo Leon, Monterey, Nuevo León, Mexico
dc.contributor.affiliation Gaines, K.A., Merck and Co. Inc., Whitehouse Station, NJ, United States
dc.contributor.affiliation Verbruggen, N., Merck Sharp and Dohme Inc. (Europe), Brussels, Belgium
dc.contributor.affiliation Melton, M.E., Merck and Co. Inc., Whitehouse Station, NJ, United States
dc.contributor.authorAddress Kendler, D.; St. Vincent's Hospital, 120-809 W 41 Avenue, Vancouver, BC V5Z 2N6, Canada; email: kendler@ca.inter.net
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision
dc.contributor.authorEmail kendler@ca.inter.net
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Kendler, D
dc.contributor.authorInitials Kung, AWC
dc.contributor.authorInitials Fuleihan, GEH
dc.contributor.authorInitials Gonzalez, JGG
dc.contributor.authorInitials Gaines, KA
dc.contributor.authorInitials Verbruggen, N
dc.contributor.authorInitials Melton, ME
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Kendler, D (reprint author), St Vincents Hosp, 120-809 W 41 Ave, Vancouver, BC V5Z 2N6, Canada.
dc.contributor.authorResearcherID Kung, Annie-C-4294-2009
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited BANNWARTH B, 1994, DRUGS, V47, P428; Biller BMK, 1999, J REPROD MED, V44, P1075; Burke WJ, 2000, J CLIN PSYCHOPHARM, V20, P423, DOI 10.1097-00004714-200008000-00006; Claxton AJ, 2001, CLIN THER, V23, P1296, DOI 10.1016-S0149-2918(01)80109-0; ERAKER SA, 1984, ANN INTERN MED, V100, P258; Gupta AK, 2000, BRIT J DERMATOL, V142, P965, DOI 10.1046-j.1365-2133.2000.03479.x; LOBEL HO, 1993, LANCET, V341, P848, DOI 10.1016-0140-6736(93)93058-9; LOBEL HO, 1991, JAMA-J AM MED ASSOC, V265, P361, DOI 10.1001-jama.265.3.361; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001-jama.288.22.2868; Nolting SK, 1998, INT J DERMATOL, V37, P454, DOI 10.1046-j.1365-4362.1998.00357.x; Ridwan E, 1996, AM J CLIN NUTR, V63, P884; RUDD P, 1995, AM HEART J, V130, P572, DOI 10.1016-0002-8703(95)90368-2; Schnitzer T, 2000, AGING-CLIN EXP RES, V12, P1; SENN S, 1993, CROSSOVER TRIALS CLI; Simon JA, 2002, CLIN THER, V24, P1871, DOI 10.1016-S0149-2918(02)80085-6
dc.description.citedCount 77
dc.description.citedTotWOSCount 68
dc.description.citedWOSCount 67
dc.format.extentCount 9
dc.identifier.articleNo
dc.identifier.coden MATUD
dc.identifier.pubmedID 15207890
dc.identifier.scopusID 2942659309
dc.identifier.url
dc.publisher.address CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Maturitas
dc.relation.ispartOfIssue 3
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Maturitas
dc.relation.ispartofPubTitleAbbr Maturitas
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 48
dc.source.ID WOS:000222567800008
dc.type.publication Journal
dc.subject.otherAuthKeyword Alendronate
dc.subject.otherAuthKeyword Osteoporosis
dc.subject.otherAuthKeyword Preference
dc.subject.otherAuthKeyword Weekly
dc.subject.otherChemCAS alendronic acid, 66376-36-1
dc.subject.otherChemCAS Alendronate, 66376-36-1
dc.subject.otherIndex alendronic acid
dc.subject.otherIndex adult
dc.subject.otherIndex clinical trial
dc.subject.otherIndex conference paper
dc.subject.otherIndex controlled clinical trial
dc.subject.otherIndex controlled study
dc.subject.otherIndex drug dose regimen
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex female
dc.subject.otherIndex human
dc.subject.otherIndex major clinical study
dc.subject.otherIndex osteoporosis
dc.subject.otherIndex patient compliance
dc.subject.otherIndex postmenopause
dc.subject.otherIndex questionnaire
dc.subject.otherIndex randomized controlled trial
dc.subject.otherIndex treatment outcome
dc.subject.otherIndex Aged
dc.subject.otherIndex Alendronate
dc.subject.otherIndex Cross-Over Studies
dc.subject.otherIndex Drug Administration Schedule
dc.subject.otherIndex Female
dc.subject.otherIndex Humans
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Osteoporosis, Postmenopausal
dc.subject.otherIndex Patient Satisfaction
dc.subject.otherIndex Questionnaires
dc.subject.otherKeywordPlus TERM MALARIA PROPHYLAXIS
dc.subject.otherKeywordPlus MEFLOQUINE
dc.subject.otherWOS Geriatrics and Gerontology
dc.subject.otherWOS Obstetrics and Gynecology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account